CT
CTEV.US Claritev Corporation
- Market cap
- USD 458M
- P/E
- -
- P/B
- 43.86x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is CTEV.US undervalued?
Graham numberThe Graham number of Claritev Corporation cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Claritev Corporation fundamental analysis
No fundamental analysis for Claritev Corporation yet.
Claritev Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Claritev Corporation
Claritev Corporation, together with its subsidiaries, provides data analytics and technology-enabled end-to-end cost management, payment, and revenue integrity solutions to the healthcare industry in the United States. The company offers claims intelligence solutions, including reference-based pricing, negotiation services, surprise bill services, and Vistara; network solutions, such as primary networks, complementary networks, and network build and network management servic…
Full company profileClaritev Corporation financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Claritev Corporation annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 1.04B | 983M | 938M | 1.12B | 1.08B | 962M | 931M | 965M | 1.03B |
| Gross Profit | 891M | 833M | 619M | 942M | 876M | 726M | 691M | 267M | 233M |
| Operating Income | 428M | 368M | -132M | 386M | -363M | 162M | -1.39B | 45.1M | 67.8M |
| EBITDA | 814M | 786M | 192M | 815M | 158M | 652M | -1.01B | 475M | 512M |
| Net Income | 36.2M | 9.71M | -521M | 102M | -573M | -91.7M | -1.65B | -284M | -259M |
| EPS | 1.32 | 0.35 | -44 | 6.27 | -36 | -5.69 | -102 | -17 | -15 |
| Balance Sheet | |||||||||
| Total Assets | - | 8.36B | 8.28B | 8.22B | 7.37B | 6.96B | 5.15B | 4.89B | 4.68B |
| Total Liabilities | - | 6.38B | 5.73B | 5.88B | 5.58B | 5.26B | 5.07B | 5.06B | 5.02B |
| Shareholders' Equity | - | 1.99B | 2.56B | 2.34B | 1.79B | 1.71B | 84.0M | -174M | -347M |
| Cash & Short-term Investments | - | 21.8M | 127M | 185M | 334M | 71.5M | 16.8M | 16.8M | 10.1M |
| Total Debt | - | 5.43B | 4.61B | 4.93B | 4.78B | 4.57B | 4.54B | 4.63B | 4.63B |
| Cash Flow | |||||||||
| Operating Cash Flow | 292M | 284M | 377M | 405M | 372M | 172M | 108M | 117M | 86.7M |
| Capital Expenditure | 63.6M | 66.4M | 70.8M | 84.6M | 89.7M | 109M | 118M | 130M | 172M |
| Free Cash Flow | 229M | 218M | 307M | 320M | 283M | 62.9M | -10.5M | -12.3M | -85.6M |
| Ratios | |||||||||
| ROE | - | 0.5% | -20.4% | 4.4% | -32.0% | -5.4% | -1,958.8% | - | - |
| ROA | - | 0.1% | -6.3% | 1.2% | -7.8% | -1.3% | -32.0% | -5.8% | -5.5% |
| Net Profit Margin | 3.5% | 1.0% | -55.5% | 9.1% | -53.1% | -9.5% | -176.9% | -29.4% | -25.3% |
| Debt to Equity | - | 2.74x | 1.80x | 2.10x | 2.67x | 2.67x | 54.05x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Claritev Corporation dividends
Claritev Corporation has not paid dividends in the last 8 fiscal years.
Last stock split: 1:40 on Sep 23, 2024.
Who owns Claritev Corporation
- Insiders 7.28%
- Institutions 84.66%
- Public & others 8.06%
- Shares outstanding 17.1M
- Free float 6.96M
Top funds holding CTEV.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 470K | 2.77% | +45.67% | Sep 2026 |
| iShares Russell 2000 ETF | 259K | 1.53% | 0.00% | Oct 2026 |
| Fidelity Small Cap Index | 109K | 0.64% | +3.13% | Aug 2026 |
| iShares Russell 2000 Value ETF | 74.3K | 0.44% | 0.00% | Oct 2026 |
| Schwab Fundamental U.S. Small CompanyETF | 68.0K | 0.40% | 0.00% | Oct 2026 |
| PIMCO RAE US S Instl | 60.1K | 0.35% | +40.74% | Jun 2026 |
| Vanguard Russell 2000 ETF | 56.7K | 0.33% | +1.29% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 48.7K | 0.29% | +0.20% | Oct 2026 |
| Fidelity Extended Market Index | 44.2K | 0.26% | +11.51% | Sep 2026 |
| iShares Micro-Cap ETF | 29.7K | 0.18% | 0.00% | Oct 2026 |
| iShares Russell 2000 Growth ETF | 26.5K | 0.16% | -0.37% | Oct 2026 |
| Schwab Small Cap Index | 23.1K | 0.14% | -4.55% | Sep 2026 |
| Schwab Fundamental US Small Company Idx | 17.6K | 0.10% | -14.50% | Sep 2026 |
| Stt Strt SPDR® Russell2000 US SmCapETF | 17.4K | 0.10% | -6.55% | Sep 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 17.3K | 0.10% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 16.6K | 0.10% | +14.20% | Sep 2026 |
| Invesco RAFI US 1500 Small-Mid ETF | 16.4K | 0.10% | 0.00% | Oct 2026 |
| iShares Core S&P Total US Stock Mkt ETF | 15.8K | 0.09% | +0.02% | Oct 2026 |
| Vanguard Health Care ETF | 15.3K | 0.09% | +0.12% | Sep 2026 |
| Bridge Builder Small Cap Fund | 13.4K | 0.08% | 0.00% | Oct 2026 |
Top institutions holding CTEV.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| H&F Corporate Investors VIII, Ltd. | 3.89M | 22.94% | 0.00% | Jun 2026 |
| Arini Captial Management Ltd | 3.07M | 18.11% | +100.00% | Jun 2026 |
| Ares Management LLC | 1.86M | 10.99% | 0.00% | Jun 2026 |
| PUBLIC INVESTMENT FUND | 1.28M | 7.56% | 0.00% | Jun 2026 |
| Beach Point Capital Management LP | 751K | 4.43% | -2.60% | Sep 2026 |
| BlackRock Inc | 723K | 4.27% | +23.00% | Jun 2026 |
| CPV Partners, LLC | 495K | 2.92% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 423K | 2.50% | -1.63% | Jun 2026 |
| Prudential Financial Inc | 354K | 2.09% | +0.05% | Jun 2026 |
| Geode Capital Management, LLC | 225K | 1.33% | +18.60% | Jun 2026 |
| Caspian Capital Partners, L.P. | 181K | 1.07% | -49.24% | Jun 2026 |
| AQR Capital Management LLC | 174K | 1.03% | +398.74% | Jun 2026 |
| State Street Corp | 170K | 1.01% | +9.49% | Jun 2026 |
| Charles Schwab Investment Management Inc | 167K | 0.99% | -28.04% | Jun 2026 |
| RBF LLC | 135K | 0.80% | 0.00% | Jun 2026 |
| Nomura Holdings Inc | 132K | 0.78% | +4.48% | Jun 2026 |
| SCOGGIN LLC | 125K | 0.74% | +41.21% | Jun 2026 |
| Bank of America Corp | 93.7K | 0.55% | -4.17% | Jun 2026 |
| Allianz Asset Management AG | 91.8K | 0.54% | +36.84% | Jun 2026 |
| Oak Hill Advisors LP | 91.8K | 0.54% | 0.00% | Jun 2026 |
Claritev Corporation company profile
- Company name
- Claritev Corporation
- Ticker
- CTEV.US
- Exchange
- USA Stocks
- Listed since
- Apr 3, 2020
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 3,000
- Fiscal year end
- December
- Address
- 7900 Tysons One Place, McLean, VA, United States, 22102
- Phone
- 866 909 7427
- Website
- claritev.com
About Claritev Corporation
Claritev Corporation, together with its subsidiaries, provides data analytics and technology-enabled end-to-end cost management, payment, and revenue integrity solutions to the healthcare industry in the United States. The company offers claims intelligence solutions, including reference-based pricing, negotiation services, surprise bill services, and Vistara; network solutions, such as primary networks, complementary networks, and network build and network management services; and payment and revenue integrity solutions comprising clinical negotiation, pre-payment integrity, post-payment integrity, and revenue integrity services. It also provides data and analytics solutions consists of PlanOptix, CompleteVue, BenInsights, risk scores, and supplemental carrier services. The company provides solutions to commercial healthcare payers, third party administrators, employers, brokers/consultants, providers, government healthcare payers and system integrators. It serves national and regional insurance companies, Blue Cross and Blue Shield plans, provider-sponsored and independent health plans, TPAs, property and casualty insurers, bill review companies and other companies involved in the claims adjudication process. The company was formerly known as MultiPlan Corporation and changed its name to Claritev Corporation in February 2025. Claritev Corporation was founded in 1980 and is headquartered in McLean, Virginia.
Claritev Corporation management
10- Mr. Travis S. DaltonCEO, President & Chairman · born 1971
- Mr. Douglas M. GarisExecutive VP & CFO · born 1985
- Mr. Jerome W. Hogge IIIExecutive VP & COO · born 1966
- Mr. Michael C. KimExecutive VP & Chief Digital Officer · born 1966
- Ms. Tiffani D. MisencikSenior VP & Chief Growth Officer · born 1973
- Mr. Brock AlbinsonSenior VP & Chief Accounting Officer · born 1975
- Mr. Todd FriedmanHead of IR & Strategic Communications
- Ms. Tara A. O'NeilChief Legal Officer · born 1966
- Ms. Kristen Lambert-KennedyChief Compliance & Chief Privacy Officer
- Mr. Alwyn Van HeerdanVice President of Strategy & Corporate Development